CSL Limited (CSLLY)
USD 80.05
(-1.09%)
USD 80.05
(-1.09%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 3.44 Billion USD | 48.1% |
| 2023 | 4.6 Billion USD | 37.6% |
| 2022 | 3.34 Billion USD | 4.33% |
| 2021 | 3.2 Billion AUD | 9.52% |
| 2020 | 2.92 Billion AUD | 10.6% |
| 2019 | 2.64 Billion AUD | 15.16% |
| 2018 | 2.3 Billion AUD | 15.67% |
| 2017 | 1.98 Billion AUD | 6.72% |
| 2016 | 1.86 Billion AUD | 30.32% |
| 2015 | 1.42 Billion AUD | -1.93% |
| 2014 | 1.45 Billion AUD | 2.34% |
| 2013 | 1.42 Billion AUD | 11.76% |
| 2012 | 1.27 Billion AUD | 4.06% |
| 2011 | 1.22 Billion AUD | 20.01% |
| 2010 | 1.02 Billion AUD | -7.93% |
| 2009 | 1.1 Billion AUD | 14.21% |
| 2008 | 970.77 Million AUD | 33.77% |
| 2007 | 725.7 Million AUD | -11.63% |
| 2006 | 821.19 Million AUD | 30.81% |
| 2005 | 627.79 Million AUD | 60.91% |
| 2004 | 390.14 Million AUD | 39.31% |
| 2003 | 280.05 Million AUD | 22.86% |
| 2002 | 227.95 Million AUD | 461.2% |
| 2001 | 40.61 Million AUD | 103.86% |
| 2000 | 19.92 Million AUD | -57.96% |
| 1999 | 47.39 Million AUD | 16.42% |
| 1998 | 40.71 Million AUD | -41.81% |
| 1997 | 69.96 Million AUD | 202.72% |
| 1996 | 23.11 Million AUD | 20.96% |
| 1995 | 19.1 Million AUD | 153.71% |
| 1994 | 7.53 Million AUD | 5.21% |
| 1993 | 7.15 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 1.9 Billion USD | 0.0% |
| 2024 FY | 4.79 Billion USD | 4.15% |
| 2024 Q1 | 1.34 Billion USD | -26.82% |
| 2024 Q2 | 1.53 Billion USD | 0.0% |
| 2023 Q1 | 1.35 Billion USD | -11.49% |
| 2023 FY | 4.6 Billion USD | 37.6% |
| 2023 Q4 | 1.83 Billion USD | 18.85% |
| 2023 Q3 | 1.54 Billion USD | -2.53% |
| 2023 Q2 | 1.58 Billion USD | 16.83% |
| 2022 Q4 | 1.53 Billion USD | 47.77% |
| 2022 Q2 | 1.18 Billion USD | 38.62% |
| 2022 FY | 3.34 Billion USD | 4.33% |
| 2022 Q3 | 1.03 Billion USD | -12.45% |
| 2022 Q1 | 856.01 Million USD | -42.97% |
| 2021 Q4 | 1.5 Billion USD | 44.15% |
| 2021 Q3 | 1.04 Billion USD | -2.25% |
| 2021 Q1 | 798.69 Million USD | -38.13% |
| 2021 Q2 | 1.06 Billion USD | 33.37% |
| 2021 FY | 3.2 Billion AUD | 9.52% |
| 2020 Q4 | 1.29 Billion USD | 21.1% |
| 2020 FY | 2.92 Billion AUD | 10.6% |
| 2020 Q2 | 1.17 Billion USD | 31.18% |
| 2020 Q1 | 894.36 Million USD | -22.37% |
| 2020 Q3 | 1.06 Billion USD | -9.15% |
| 2019 Q3 | 857.29 Million USD | 9.3% |
| 2019 FY | 2.64 Billion AUD | 15.16% |
| 2019 Q1 | 764.36 Million USD | 0.89% |
| 2019 Q4 | 1.15 Billion AUD | 34.39% |
| 2019 Q2 | 784.31 Million USD | 2.61% |
| 2018 Q2 | 565.07 Million USD | 0.5% |
| 2018 Q3 | 729.92 Million USD | 29.17% |
| 2018 Q4 | 757.62 Million AUD | 3.8% |
| 2018 FY | 2.3 Billion AUD | 15.67% |
| 2018 Q1 | 562.25 Million USD | -17.0% |
| 2017 Q2 | 559.44 Million USD | 6.07% |
| 2017 Q1 | 527.41 Million USD | -9.11% |
| 2017 FY | 1.98 Billion AUD | 6.72% |
| 2017 Q4 | 677.41 Million AUD | -0.6% |
| 2017 Q3 | 681.47 Million USD | 21.81% |
| 2016 Q3 | 562.48 Million USD | 40.21% |
| 2016 Q4 | 580.29 Million AUD | 3.17% |
| 2016 FY | 1.86 Billion AUD | 30.32% |
| 2016 Q2 | 401.16 Million USD | -3.47% |
| 2016 Q1 | 415.56 Million USD | 7.98% |
| 2015 Q3 | 388.36 Million USD | 26.54% |
| 2015 Q2 | 306.91 Million USD | 6.9% |
| 2015 Q1 | 287.1 Million USD | -4.76% |
| 2015 FY | 1.42 Billion AUD | -1.93% |
| 2015 Q4 | 384.86 Million AUD | -0.9% |
| 2014 Q3 | 306.63 Million USD | 4.47% |
| 2014 FY | 1.45 Billion AUD | 2.34% |
| 2014 Q1 | 280.83 Million USD | -9.59% |
| 2014 Q4 | 301.45 Million AUD | -1.69% |
| 2014 Q2 | 293.51 Million USD | 4.51% |
| 2013 FY | 1.42 Billion AUD | 11.76% |
| 2013 Q2 | 245.94 Million USD | -0.06% |
| 2013 Q4 | 310.6 Million AUD | 13.7% |
| 2013 Q1 | 246.09 Million USD | 0.0% |
| 2013 Q3 | 273.18 Million USD | 11.08% |
| 2012 FY | 1.27 Billion AUD | 4.06% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | 1.22 Billion AUD | 20.01% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 1.02 Billion AUD | -7.93% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 1.1 Billion AUD | 14.21% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 970.77 Million AUD | 33.77% |
| 2007 FY | 725.7 Million AUD | -11.63% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | 821.19 Million AUD | 30.81% |
| 2005 FY | 627.79 Million AUD | 60.91% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 FY | 390.14 Million AUD | 39.31% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | 280.05 Million AUD | 22.86% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | 227.95 Million AUD | 461.2% |
| 2001 FY | 40.61 Million AUD | 103.86% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 FY | 19.92 Million AUD | -57.96% |
| 2000 Q4 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | 47.39 Million AUD | 16.42% |
| 1998 FY | 40.71 Million AUD | -41.81% |
| 1998 Q4 | - AUD | 0.0% |
| 1997 FY | 69.96 Million AUD | 202.72% |
| 1997 Q4 | - AUD | 0.0% |
| 1996 FY | 23.11 Million AUD | 20.96% |
| 1995 FY | 19.1 Million AUD | 153.71% |
| 1994 FY | 7.53 Million AUD | 5.21% |
| 1993 FY | 7.15 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -258168.679% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -68304.798% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -11570.558% |
| Nascent Biotech, Inc. | 2.22 Million USD | -154572.07% |
| Rebus Holdings, Inc. | 664 Thousand USD | -519327.711% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -9157.651% |
| Qrons Inc. | 643.67 Thousand USD | -535727.752% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -885244.204% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -5904.526% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -830026.192% |
| Skye Bioscience, Inc. | 13.54 Million USD | -25358.478% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -3874.189% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -70031.375% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1317690.361% |
| SQZ Biotechnologies Company | 85.61 Million USD | -3928.311% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -118168.932% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -229542.606% |
| Mesoblast Limited | 5.9 Million USD | -58337.818% |
| Marizyme, Inc. | 19.23 Million USD | -17826.352% |
| Genus plc | 147.7 Million USD | -2235.139% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -39185.888% |
| Pharming Group N.V. | 225.49 Million USD | -1429.551% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -168250.251% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -256991.637% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -41259.875% |
| ContraFect Corporation | 56.88 Million USD | -5962.683% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -78132.175% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -233137.216% |
| IMV Inc. | 37.7 Million USD | -9046.305% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -123504.256% |
| MultiCell Technologies, Inc. | 567.42 USD | -607838890.518% |
| ONE Bio Corp. | 6.44 Million USD | -53423.554% |
| Accustem Sciences Inc. | 3.74 Million USD | -91961.246% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -3913.032% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -648254.582% |
| Q BioMed Inc. | 3.43 Million USD | -100260.004% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -13855.088% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -131164.362% |
| Biomind Labs Inc. | 994.18 Thousand USD | -346818.371% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -3372.258% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -195901.769% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -51239.57% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -184895.468% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 13796100.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -21442.467% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -187846.673% |
| GB Sciences, Inc. | 1.42 Million USD | -242700.292% |
| Alpha Cognition Inc. | 9.7 Million USD | -35436.182% |
| HST Global, Inc. | 140.9 Thousand USD | -2447613.74% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -306502.306% |
| Halberd Corporation | 74.84 Thousand USD | -4608274.977% |
| Enzolytics Inc. | 2.17 Million USD | -158146.796% |
| Agentix Corp. | 1.37 Million USD | -251329.555% |
| Resverlogix Corp. | 12.71 Million USD | -27031.844% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -94374.851% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | -124.906% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -330263.985% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -143313.499% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -218280.288% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -101192.842% |
| AVAX Technologies, Inc. | 7.31 Million USD | -47080.239% |
| Zenith Capital Corp. | 8.94 Million USD | -38466.477% |
| Genscript Biotech Corporation | 825.34 Million USD | -317.886% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -19797845.009% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -140370.66% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2010873.185% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -179450.691% |
| Kadimastem Ltd | 2.41 Million USD | -143005.383% |
| Helix BioMedix, Inc. | 1.97 Million USD | -174795.565% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -31638.29% |
| BioStem Technologies, Inc. | 22.97 Million USD | -14912.099% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1900332.543% |
| LadRx Corporation | 3.81 Million USD | -90382.401% |
| Cell Source, Inc. | 4.32 Million USD | -79639.286% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -373366.449% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -373366.449% |
| NovAccess Global Inc. | 2.46 Million USD | -139718.977% |
| Affymax, Inc. | 39.38 Million USD | -8656.919% |
| Itoco Inc. | 919.14 Thousand USD | -375140.849% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -81274.778% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -308121.626% |
| Mobile Lads Corp. | 554.54 Thousand USD | -621850.208% |
| CytoDyn Inc. | 18.05 Million USD | -18999.568% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -13703265.251% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1567071.639% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -242822.907% |
| SYBLEU INC | 160.87 Thousand USD | -2143787.217% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -189789.447% |
| International Stem Cell Corporation | 5.27 Million USD | -65333.504% |
| Bioxytran, Inc. | 3.82 Million USD | -90184.484% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6551702.743% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -16954134.872% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -9410.285% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -213064.4% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -468619.21% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -110764.674% |
| Neutra Corp. | 243.82 Thousand USD | -1414462.322% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -19657.117% |
| PureTech Health plc | 144.59 Million USD | -2285.25% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -16732.693% |
| IXICO plc | 4.7 Million USD | -73173.847% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -39106.548% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -2829.137% |
| CSL Limited | 3.89 Billion USD | 11.405% |
| Cellectis S.A. | 97.32 Million USD | -3443.979% |